Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scans may predict chemo and radiation damage in breast cancer patients

NCT ID NCT04790266

Knowledge-focused Sponsor: Oncology Institute of Southern Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether special heart MRI scans can spot early signs of heart damage in breast cancer patients after chemotherapy and radiation. Researchers followed 150 women for 12 months to see if heart swelling predicted a drop in heart function. The goal was to improve early detection and prevent long-term heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Sep 2020

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female patients aged ≥ 18 years with stage I-III breast cancer treated with radiation therapy and neo/adjuvant chemo/immunotherapy +/- aromatase inhibitor/tamoxifen/LhRh agonist. An ancillary study will enroll also stage 0 patients

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed 2. Age ≥ 18 years at visit 1 3. Performance status ECOG 0-1 4. \*Stage I-III histology proven breast cancer 5. Treated with adjuvant radiotherapy and neo/adjuvant anthracycline and/or trastuzumab-based therapy +/- hormonal therapy 6. Negative pregnancy test (plasma HCG) for all females of childbearing potential (i.e not permanently sterilised- post hysterectomy or tubal ligation status) In the ancillary study patients with stage 0 (DCIS) histology proven breast cancer will also be included. Exclusion Criteria: 1. Known metastatic spread of any cancer 2. Known active or recurrent hepatic disorder (cirrhosis, hepatitis), ASAT/ALAT 2xULN 3. Renal function decrease (eGFR \< 30 ml/min) 4. Known coronary artery disease 5. Angina pectoris 6. Positive or missing pregnancy test (pre- and perimenopausal women) at enrolment visit 7. Patients with baseline LVEF \<53% and GLS \<15% 8. Patients with pacemaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity

Contacts and locations

Locations

  • Oncology Institute of Italian Switzerland

    Bellinzona, Canton Ticino, 6500, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.